CD8A and glioblastoma: Co-administration with anti-PD-L1 monoclonal antibodies enhanced CD8+ T-cell responses and prolonged survival in orthotopic GBM models, illustrating the potential of combining oxidative strategies with immune checkpoint inhibition [290].